Background: Methacholine-induced bronchoconstriction is associated with significant hypoxemia, which can be assessed noninvasively by transcutaneous oxygen tension and pulse oximetry. Objectives: To assess the value of the monitoring of finger pulse oximetry during routine methacholine challenges in a clinical pulmonary function laboratory with regard to both safety and the possibility that a significant fall in oxygen saturation as measured by pulse oximetry (SpO 2 ) might be a useful surrogate for determining the response to methacholine. Methods: Two hundred consecutive patients undergoing diagnostic methacholine challenges in the pulmonary function laboratory of a tertiary-care, university-based referral hospital were studied. Methacholine challenges were performed by the standardized 2-min tidal breathing technique, and the ⌬FEV 1 was calculated from the lowest postsaline solution inhalation to the lowest postmethacholine inhalation value. SpO 2 was measured immediately prior to each spirogram, and the ⌬SpO 2 was measured from the lowest postsaline solution inhalation value to the lowest postmethacholine inhalation value. We examined the data for safety (ie, any SpO 2 value < 90). Based on previous reports, we used a ⌬SpO 2 of > 3 as significant and looked at the sensitivity, specificity, and positive and negative predictive values for ⌬SpO 2 > 3 vis-à -vis a fall in FEV 1 of > 15%. Results: There were 119 nonresponders (⌬FEV 1 , < 15%) and 81 responders. The baseline FEV 1 percent predicted was slightly but significantly lower in the responders (responders [؎ SD], 91.6 ؎ 15%; nonresponders, 96.4 ؎ 14%; p < 0.05). ⌬SpO 2 was 3.1 ؎ 1.6 in the responders and 1.6 ؎ 1.8 in the nonresponders (p < 0.001). There was a single recording in one patient of SpO 2 < 90 (88). A ⌬SpO 2 > 3 had a sensitivity of 68%, a specificity of 73%, a positive predictive value of 63%, and negative predictive value of 77% for a fall in FEV 1 > 15%. Conclusions: Pulse oximetry is not routinely useful for safety monitoring during methacholine challenge. ⌬SpO 2 is not helpful in predicting a positive spirometric response to methacholine. However, the negative predictive value is adequate to allow the ⌬SpO 2 to be used as an adjunct in assessing a negative result of a methacholine test in patients who have difficulty performing spirometry.
B
ronchoprovocation with methacholine results in a significant fall in the arterial oxygen level. [1] [2] [3] [4] [5] [6] [7] [8] A 20% fall in FEV 1 (or an equivalent change in other measures of airflow) is associated with an average fall in Pao 2 (measured transcutaneously) of 15 to 20%, [3] [4] [5] [6] [7] or an average fall in oxygen saturation measured by pulse oximetry (Spo 2 ) of about 3%. [1] [2] [3] 8 In our laboratory, pulse oximetry is used during methacholine challenges to monitor oxygenation in infrequent patients (ie, Յ 0.5% of patients) who develop severe dyspnea or, rarely, to monitor continuously those patients with low baseline Spo 2 values (low 90%). Pulse oximetry is also occasionally used as an adjunct to, or instead of, spirometry to assess patients for objective responses.
The current investigation was designed to assess the value of pulse oximetry by looking at 200 consecutive patients undergoing diagnostic methacholine challenges in the pulmonary function laboratory.
The potential values of interest were two. First, we wished to determine whether this should be a routine requirement for safety purposes. Second, we wished to obtain some objective data regarding the performance of Spo 2 as a surrogate for FEV 1 in selected subjects who have difficulty performing spirometry for one reason or other.
Materials and Methods

Subjects
Two hundred consecutive patients undergoing diagnostic methacholine challenges were studied prospectively. The 200 subjects analyzed all had a fall in FEV 1 Ն 15% or received the top concentration of methacholine (8 mg/mL). Subjects for methacholine challenge were expected to have an FEV 1 Ͼ 70% of predicted. 9 Since pulse oximetry is noninvasive and was already occasionally performed during methacholine challenges in our laboratory, ethics committee approval and informed consent were not obtained.
Methacholine Challenge
The methacholine challenge used in our laboratory is the standardized 2-min tidal breathing technique 10 with test-shortening modifications, as per current guidelines. 11 Aerosols are generated with a nebulizer (Twin Jet; Puritan Bennett Corp; Carlsbad, CA) driven by compressed air and calibrated to give an output of 0.13 mL/min (0.26 mL/2 min). Spirometry is initially performed in duplicate. The patient's nose is clipped, and a saline aerosol is delivered via a loose-fitting face mask and inhaled for 2 min with quiet tidal breathing. Spirometry is repeated once at 30 s and once at 90 s. Doubling concentrations of methacholine then are inhaled with 5-min intervals between the start of one concentration and the start of the next concentration. Spirometry is repeated in the same fashion. The concentrations of methacholine available are 0.03 to 8 mg/mL or, occasionally, 16 mg/mL. Methacholine inhalations are started based on clinical guidelines, 11 which would often be 1 mg/mL in the diagnostic laboratory in subjects with normal lung function. The percentage fall in FEV 1 is calculated from the lowest postsaline solution aerosol inhalation to the lowest postmethacholine inhalation value, 10, 12 and the provocative concentration of a substance causing a 20% fall in FEV 1 (PC 20 ) then is interpolated 13 or extrapolated 14 using algebraic formulae. For the purposes of this study, the PC 20 was not examined.
Pulse Oximetry
Pulse oximetry was measured continuously with a pulse oximeter (model NPB-4000; Nellcor Puritan Bennett Canada Ltd; Oakville, Ontario, Canada). Spo 2 was displayed as a running mean over the last three heart beats. To minimize motion artifacts, we measured the pulse using the hand, which was at rest holding neither the nebulizer nor the spirometer. Oxygen saturation was recorded immediately prior to each spirogram maneuver. This was important because we observed that induced falls in Spo 2 often reversed rapidly with a deep inhalation. There was, therefore, a measurement of Spo 2 both before and at 30 and 90 s after each inhalation. The ⌬Spo 2 was calculated to be analogous to the ⌬FEV 1 using the lowest postsaline solution aerosol inhalation value to the lowest postmethacholine inhalation value.
Analysis
This was primarily a descriptive study. We examined for instances of oxygen desaturation that were defined as an Spo 2 Ͻ 90%. An Spo 2 Ͻ 90% corresponds approximately to a Pao 2 Ͻ 60 mm Hg, which represents significant hypoxemia and approaches the steep part of the oxygen-hemoglobin dissociation curve. Since methacholine challenges are frequently stopped at the point between a 15% and 20% fall in FEV 1 in our laboratory, and the PC 20 is then extrapolated, 14 we used a Ն 15% fall in FEV 1 as the spirometric end point. We used an unpaired two-tailed t test to compare baseline physiologic variables and the ⌬Spo 2 in responders (ie, ⌬FEV 1 Ն 15%) and nonresponders.
We examined various cut points for a change in Spo 2 , however, based on the published data that the average ⌬Spo 2 ; with a positive methacholine test was about 3%, [1] [2] [3] 8 we examined a ⌬Spo 2 of Ն 3%. We then applied the standard diagnostic test criteria (ie, sensitivity, specificity, positive predictive value, and negative predictive value 15 ) for the performance of a ⌬Spo 2 Ն 3%, with the comparator being a ⌬FEV 1 Ն 15%.
Results
The age range of the 200 subjects was 11 to 85 years, with good representation of subjects from 15 to 75 years but with only 2 subjects who were Ͻ 15 years and 3 subjects who were Ͼ 75 years. Results may, therefore, not necessarily be extrapolated to the very young or very old. The 200 subjects were divided into responders (⌬FEV 1 Ն 15%; n ϭ 81) and nonresponders (⌬FEV 1 Ͻ 15%; n ϭ 119). Subject characteristics are shown in Table 1 . There was no difference in anthropometric values. Physiologic values were similar; the only significant difference was a slightly lower percent predicted FEV 1 (Ϯ SD) in the responders (91.6 Ϯ 15%) vs the nonresponders (96.4 Ϯ 14%) (p Ͻ 0.05). Baseline FEV 1 was Ͼ 70% of predicted in 96% of subjects and Ͻ 70% in 4% of subjects (n ϭ 8), including six responders and two nonresponders. There was a single recording of Spo 2 Ͻ 90% in one subject on one occasion. Spo 2 was 88% but rose promptly with the performance of the spirogram. This represents 1 of 200 individuals (0.5%) or 1 of 2,246 measurements (0.04%).
The ⌬Spo 2 was 1.6 Ϯ 1.8% in the nonresponders and 3.1 Ϯ 1.6% in the responders (p Ͻ 0.001). The number of subjects with different values for ⌬Spo 2 in the responders and nonresponders is shown in Table 2 . The sensitivity-specificity table for ⌬Spo 2 Ն 3% and ⌬FEV 1 Ն 15% is shown in Table 3 . A Ն 3% fall in saturation had a 68% sensitivity, a 73% specificity, a 63% positive predictive value, and a 77% negative predictive value for a Ն 15% fall in FEV 1 . The magnitude of the ⌬Spo 2 was not significantly different at different methacholine concentrations in the responders (Table 4) .
Discussion
These data indicate that routine pulse oximetry is not necessary from a safety perspective and is not helpful in predicting a positive spirometric response to methacholine. The 77% negative predictive value suggests that oxygen saturation monitoring might be of value in helping to exclude a positive spirometric response to methacholine.
In a specialty referral practice, it is not uncommon to encounter patients who cannot perform spirometry. Some of these encounters may represent genuine lack of comprehension of the test. However, in our experience, many of these individuals are either compensation or disability patients, or, alternatively, have a history suggestive of some degree of psychogenic respiratory problems. In such individuals, asthma is often part of the differential diagnosis, and a reliable method to exclude the diagnosis of current symptomatic asthma would be valuable. Traditionally, a technically interpretable methacholine challenge, because of its extremely high sensitivity for current symptoms of asthma, 16 has been used to exclude asthma. In patients with uninterpretable spirometry results, we have occasionally performed methacholine challenges, single blinded as to intention if at all possible (this point is often difficult to ascertain), using lack of symptoms, lack of audible wheezing, and lack of change in oxygen saturation as an indication of a probable negative spirometric response to methacholine. The 77% negative predictive value (ie, 77% of the spirometrically negative methacholine challenges also had a Ͻ 3% fall in Spo 2 ) provides objective data that validate the use of ⌬Spo 2 as an adjunct to symptoms and wheezing for the interpretation of a negative result to methacholine challenge. We have much less confidence in the value of oxygen saturation monitoring in predicting a positive spirometric response to methacholine.
This study was not performed to address mechanisms. It seems, however, inescapable that the mechanism of methacholine-induced hypoxemia must be related to worsening ventilation-perfusion matching. To oversimplify things, worsened ventilation-perfusion matching must be due to bronchoconstriction, vasodilation, or a combination. The effects of muscarinic agonists on the pulmonary vasculature are not well understood. It appears that the primary effect is vasoconstrictive, 17 while there are some data to support an additional vasodilator effect of acetylcholine. 18 It is most likely that the methacholine-induced hypoxemia is related to an impairment in ventilation that is not always captured by forced expiratory maneuvers performed after inspiration to total lung capacity. Inhalation to total lung capacity can result in the rapid reversal of induced bronchoconstriction, particularly in healthy subjects and mildly hyperresponsive individuals. 19 It is probable that this is the explanation for falls in saturation levels in individuals who fail to show measurable changes in their spirogram. This would also be in keeping with our observation that falls in saturation (whether or not accompanied by falls in FEV 1 ) often rapidly reverse with a deep inspiration. It is likely that such transient falls in Spo 2 would be less likely to occur using the "five inspiratory capacity breath" method of methacholine inhalation. Although the routine monitoring of Spo 2 during methacholine challenges is not necessary, it remains prudent to have a pulse oximeter available for emergency use in guiding oxygen therapy in the rare patient who requires intensive treatment of postmethacholine inhalation bronchospasm.
In conclusion, while a positive result of a methacholine challenge, here defined as a Ն 15% fall in FEV 1 , is associated with an average fall in oxygen saturation of Ն 3%, the use of oxygen saturation is not helpful in predicting a positive spirometric response to methacholine. Nor does it seem to be of value or to be a necessity as a safety precaution in subjects undergoing routine methacholine challenges. The good negative predictive value may provide a role for oxygen saturation monitoring in conjunction with other nonspirometric end points in the interpretation of a negative result for a methacholine challenge.
